Miscellaneous Perianal Afflictions

Gonzalo F. Hagerman; Jorge Silva-Velazco; Juan Francisco Molina-Lopez

doi:10.1055/s-0039-1687836

Clinics in Colon and Rectal Surgery, Table of Contents

Clin Colon Rectal Surg 2019; 32(05): 394-402
DOI: 10.1055/s-0039-1687836

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Miscellaneous Perianal Afflictions

Authors

Gonzalo F. Hagerman

¹Department of Surgery, ABC Medical Center, Mexico City, Mexico
Jorge Silva-Velazco

¹Department of Surgery, ABC Medical Center, Mexico City, Mexico
Juan Francisco Molina-Lopez

¹Department of Surgery, ABC Medical Center, Mexico City, Mexico

Abstract

This article provides an overview of hidradenitis suppurativa, lichen planus, lichen sclerosis, calcinosis cuti, pyogenic granuloma, intertrigo, and seborrheic keratosis. This article also focuses on recognition and management of these pleomorphic afflictions of the perianal region.

Keywords

hidradenitis suppurativa - lichen planus - lichen sclerosis - calcinosis cuti - pyogenic granuloma - intertrigo and seborrheic keratosis

Full Text

References

References
1 Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366 (02) 158-164
2 Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol 2009; 61 (02) 362-365
3 Revuz JE, Canoui-Poitrine F, Wolkenstein P. , et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59 (04) 596-601
4 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35 (2 Pt 1): 191-194
5 Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68 (03) 412-419
6 Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133 (01) 97-103
7 van der Zee HH, de Ruiter L, Boer J. , et al. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166 (01) 98-106
8 Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135 (05) 721-725
9 von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010; 19 (06) 533-537
10 von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164 (02) 367-371
11 van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 2011; 164 (06) 1292-1298
12 Kamp S, Fiehn AM, Stenderup K. , et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are significantly reduced in uninvolved hair follicles from patients with hidradenitis suppurativa. Br J Dermatol 2011; 164 (05) 1017-1022
13 Von Der Werth JM, Williams HC, Raeburn JA. The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 2000; 142 (05) 947-953
14 Wang B, Yang W, Wen W. , et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330 (6007): 1065
15 Pink AE, Simpson MA, Desai N, Trembath RC, Barker JNW. γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 2013; 133 (03) 601-607
16 Pink AE, Simpson MA, Brice GW. , et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa). J Invest Dermatol 2011; 131 (07) 1568-1570
17 Deckers IE, van der Zee H, Prens EP. Epidemiology of hidradenitis suppurativa: Prevalence, pathogenesis, and factors associated with the development of HS. Curr Dermatol Rep 2014; 3 (01) 54-60
18 Nazary M, van der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 2011; 672 (1-3): 1-8
19 Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65 (04) 790-798
20 Dréno B, Khammari A, Brocard A. , et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 2012; 148 (02) 182-186
21 Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161 (04) 831-839
22 Happle R, König A. Smoker's boils. Dermatology 2011; 222 (03) 282-284
23 Kurzen H, Kurokawa I, Jemec GB. , et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008; 17 (05) 455-456 , discussion 457–472
24 Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60 (04) 539-561 , quiz 562–563
25 Bettoli V, Zauli S, Borghi A. , et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol 2014; 28 (01) 125-126
26 von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14 (05) 389-392
27 Canoui-Poitrine F, Le Thuaut A, Revuz JE. , et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 2013; 133 (06) 1506-1511
28 Chicarilli ZN. Follicular occlusion triad: hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp. Ann Plast Surg 1987; 18 (03) 230-237
29 Church JM, Fazio VW, Lavery IC, Oakley JR, Milsom JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis 1993; 8 (03) 117-119
30 Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2 (01) 9-16
31 van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162 (01) 195-197
32 Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010; 146 (11) 1265-1270
33 Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001; 137 (06) 730-734
34 Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140 (01) 90-95
35 Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk Jr HH. , eds. Dermatologic Surgery–Principles and Practice. New York: Marcel Dekker; 1989: 729-739
36 Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158 (02) 370-374
37 Kimball AB, Kerdel F, Adams D. , et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157 (12) 846-855
38 Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22 (05) 325-328
39 Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 2017; 318 (20) 2019-2032
40 Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol 2016; 41 (08) 852-857
41 Armyra K, Kouris A, Markantoni V, Katsambas A, Kontochristopoulos G. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients. Int J Dermatol 2017; 56 (03) 346-350
42 Join-Lambert O, Coignard-Biehler H, Jais JP. , et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother 2016; 71 (02) 513-520
43 Kimball AB, Okun MM, Williams DA. , et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375 (05) 422-434
44 Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174 (04) 839-846
45 Tzanetakou V, Kanni T, Giatrakou S. , et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol 2016; 152 (01) 52-59
46 Madan V, Hindle E, Hussain W, August PJ. Outcomes of treatment of nine cases of recalcitrant severe hidradenitis suppurativa with carbon dioxide laser. Br J Dermatol 2008; 159 (06) 1309-1314
47 Kohorst JJ, Baum CL, Otley CC. , et al. Surgical management of hidradenitis suppurativa: Outcomes of 590 consecutive patients. Dermatol Surg 2016; 42 (09) 1030-1040
48 Janse I, Bieniek A, Horváth B, Matusiak Ł. Surgical procedures in hidradenitis suppurativa. Dermatol Clin 2016; 34 (01) 97-109
49 Mehdizadeh A, Hazen PG, Bechara FG. , et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol 2015; 73 (05) (Suppl. 01) S70-S77
50 Riis PT, Boer J, Prens EP. , et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol 2016; 75 (06) 1151-1155
51 Rambhatla PV, Lim HW, Hamzavi I. A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012; 148 (04) 439-446
52 Billingham RP, Isler JT, Kimmins MH, Nelson JM, Schweitzer J, Murphy MM. The diagnosis and management of common anorectal disorders. Curr Probl Surg 2004; 41 (07) 586-645
53 Gaertner WB. Dermatology and pruritus ani. In: Steele SR, Hull TL, Read TE, Saclarides TJ, Senagore AJ, Whitlow CB. , eds. The ASCRS Textbook of Colon and Rectal Surgery. New York: Springer; 2016: 309-324
54 Alexander-Williams J. Pruritus ani. Br Med J (Clin Res Ed) 1983; 287 (6386): 159-160
55 Hanno R, Murphy P. Pruritus ani. Classification and management. Dermatol Clin 1987; 5 (04) 811-816
56 Harrington CI, Lewis FM, McDonagh AJ, Gawkrodger DJ. Dermatological causes of pruritus ani. BMJ 1992; 305 (6859): 955
57 Verbov J. Pruritus ani and its management--a study and reappraisal. Clin Exp Dermatol 1984; 9 (01) 46-52
58 Saurat JHLP. Lichen ruber planus e dermatosi lichenoidi. In: Saurat JH, Grosshans E, Laugier P, Lachapelle JM. , eds. Manuale di dermatologia e venereologia. Milano: Masson; 1995: 341
59 Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol 1991; 25 (04) 593-619
60 Lichen planus clinical presentation: History, physical examination, causes. https://emedicine.medscape.com/article/1123213-clinical#b2 . Accessed 12/18/2017, 2017
61 Fundarò S, Spallanzani A, Ricchi E. , et al. Squamous-cell carcinoma developing within anal lichen planus: report of a case. Dis Colon Rectum 1998; 41 (01) 111-114
62 Arndt KA. Lichen planus. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF. , eds. Dermatology in general medicine. 4th edition. New York: McGraw Hill; 1993: 1134
63 Ruocco V, Satriano RA, De Rosa G, Pettinato G, Gombos F. Malignancy in lichen planus. Int J Dermatol 1989; 28 (08) 542-544
64 Lichen planus treatment: https://emedicine.medscape.com/article/1123213-treatment . Updated 12/18/ 2017
65 Nasseri YY, Osborne MC. Pruritus ani: diagnosis and treatment. Gastroenterol Clin North Am 2013; 42 (04) 801-813
66 Zuccati G, Lotti T, Mastrolorenzo A, Rapaccini A, Tiradritti L. Pruritus ani. Dermatol Ther 2005; 18 (04) 355-362
67 Smith LE. Perianal dermatologic disease. In: Gordon PH, Nivatvongs S. , eds. Principles and practice of surgery for the colon, rectum, and anus. 3rd edition. New York: Informa Healthcare; 2007: 247-260
68 Lichen sclerosis; Workup. https://emedicine.medscape.com/article/1123316-workup#c1
69 Borghi A, Corazza M, Minghetti S, Bianchini E, Virgili A. Dermoscopic features of vulvar lichen sclerosus in the setting of a prospective cohort of patients: New observations. Dermatology 2016; 232 (01) 71-77
70 Val I, Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol 2005; 48 (04) 808-817
71 Siddiqi S, Vijay V, Ward M, Mahendran R, Warren S. Pruritus ani. Ann R Coll Surg Engl 2008; 90 (06) 457-463
72 Carli P, Cattaneo A, De Magnis A, Biggeri A, Taddei G, Giannotti B. Squamous cell carcinoma arising in vulval lichen sclerosus: a longitudinal cohort study. Eur J Cancer Prev 1995; 4 (06) 491-495
73 Neill SM, Tatnall FM, Cox NH. ; British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol 2002; 147 (04) 640-649
74 Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol 2003; 48 (06) 935-937
75 Sheth S, Schechtman AD. Itchy perianal erythema. J Fam Pract 2007; 56 (12) 1025-1027
76 Touart DM, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol 1998; 39 (4 Pt 1): 527-544 , quiz 545–546
77 Balcı DD, Celik E, Sarıkaya G, Yenin JZ, Atik E. The co-existence of vulvar lichen sclerosus, ulcerated calcinosis cutis, and dermatomyositis: coincidence or immunological mechanism?. Ann Dermatol 2011; 23 (Suppl. 03) S375-S379
78 Gutierrez Jr A, Wetter DA. Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther (Heidelb) 2012; 25 (02) 195-206
79 Valenzuela A, Chung L. Calcinosis: pathophysiology and management. Curr Opin Rheumatol 2015; 27 (06) 542-548
80 Jiménez-Gallo D, Ossorio-García L, Linares-Barrios M. Calcinosis cutis and Calciphylaxis. Actas Dermosifiliogr 2015; 106 (10) 785-794
81 Dima A, Balanescu P, Baicus C. Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases. Rom J Intern Med 2014; 52 (02) 55-67
82 Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 2011; 65 (01) 15-22 , quiz 23–24
83 Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012; 148 (04) 455-462
84 Kalra MG, Higgins KE, Kinney BS. Intertrigo and secondary skin infections. Am Fam Physician 2014; 89 (07) 569-573
85 Janniger CK, Schwartz RA, Szepietowski JC, Reich A. Intertrigo and common secondary skin infections. Am Fam Physician 2005; 72 (05) 833-838
86 Guitart J, Woodley DT. Intertrigo: a practical approach. Compr Ther 1994; 20 (07) 402-409
87 Del Rosso JQ, Draelos ZD, Jorizzo JL, Joseph WS, Ribotsky BM, Rich P. Modern methods to treat superficial fungal disease. Cutis 2007; 79 (2, Suppl): 6-29
88 Holdiness MR. Management of cutaneous erythrasma. Drugs 2002; 62 (08) 1131-1141
89 Stulberg DL, Penrod MA, Blatny RA. Common bacterial skin infections. Am Fam Physician 2002; 66 (01) 119-124
90 Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008; 6 (08) 664-677